ImmunityBio (IBRX) Net Cash Flow Growth (5y) (2019 - 2026)

ImmunityBio (IBRX) Net Cash Flow Growth (5y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 ImmunityBio 7.60 Bn 7.22 Bn 43.97 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 63.93%
Dec 31, 2025 20.73%
Sep 30, 2025 -20.33%
Jun 30, 2025 6.32%
Mar 31, 2025 -36.86%
Dec 31, 2024 28.65%
Sep 30, 2024 -91.59%
Jun 30, 2024 13.13%
Mar 31, 2024 -85.36%
Dec 31, 2023 125.20%
Sep 30, 2023 178.52%
Jun 30, 2023 -61.91%
Mar 31, 2023 -4.64%
Dec 31, 2022 -35.92%
Sep 30, 2022 34.06%
Jun 30, 2022 -0.03%
Mar 31, 2022 -95.03%
Dec 31, 2021 47.56%
Sep 30, 2021 -23.36%
Jun 30, 2021 28.97%